Cargando…
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical...
Autores principales: | Williams, C. J., Barley, V. L., Blackledge, G. R., Rowland, C. G., Tyrrell, C. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968660/ https://www.ncbi.nlm.nih.gov/pubmed/8260375 |
Ejemplares similares
-
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984) -
Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs
por: Macfarlane, L., et al.
Publicado: (2016) -
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985)